Featured Research

from universities, journals, and other organizations

Collaboration Advances Potential Therapy For Autoimmune Diseases

Date:
June 4, 2002
Source:
Pacific Northwest National Laboratory
Summary:
The Department of Energy's Pacific Northwest National Laboratory has launched a collaboration with two U.S. companies and Russian scientists to develop a more effective treatment for autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, which afflict nearly 50 million Americans. The collaboration represents the latest commercial venture between a former Russian weapons facility, a DOE national laboratory and U.S. industry under DOE's Initiatives for Proliferation Prevention program (IPP).

RICHLAND, Wash. -- The Department of Energy's Pacific Northwest National Laboratory has launched a collaboration with two U.S. companies and Russian scientists to develop a more effective treatment for autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, which afflict nearly 50 million Americans. The collaboration represents the latest commercial venture between a former Russian weapons facility, a DOE national laboratory and U.S. industry under DOE's Initiatives for Proliferation Prevention program (IPP).

Related Articles


Through a Cooperative Research and Development Agreement, Advanced Biotherapy Inc. of Woodland Hills, Calif., and New Horizon Diagnostics Inc. of Columbia, Md., will hold nonexclusive licenses to inventions created by scientists at the Institute of Immunological Engineering of Moscow or by PNNL researchers through this program.

The Russian scientists have created unique humanized antibodies to gamma interferon, a protein that when overproduced triggers and exacerbates various autoimmune conditions. This work is a major step toward creating a much-improved treatment for certain autoimmune diseases. Until recently, most treatments employed antibodies derived from mice, which were effective but could be used only one or two times before the human body rejected them. Antibodies are proteins that bind to and disable foreign proteins, called antigens. With fully humanized antibodies, the human body potentially could accept them over longer periods of time, thus providing for long-term treatment.

The Russian research, coupled with a treatment method developed by Advanced Biotherapy, appears promising. During the past year, PNNL scientists have worked closely with the Russians to verify research results, monitor progress and identify and secure a viable commercial partner. PNNL is the technical lead for most biological and chemical-related projects conducted throughout several national laboratories for IPP.

"This agreement will allow us to leverage the incredible expertise found in the Russian institutions and in these companies," said Richard Weller, PNNL principal investigator. "Our main objective is to make it possible for these organizations to develop a therapy that will remove the symptoms of these painful diseases so people can live better lives."

Of the 50 million Americans suffering from autoimmune diseases, nearly 75 percent of those are women, according to the American Autoimmune-Related Diseases Association. Arthritis, an autoimmune disease, is the leading cause of disability in the United States and will impact nearly 60 million Americans by 2020, according to the Centers for Disease Control. Other autoimmune diseases include lupus, insulin-dependent diabetes and arthritis of the spine. These diseases erupt when the immune system mistakenly attacks itself rather than protects itself. While the root causes of these attacks largely are unknown to scientists, results can be organ-specific disorders, such as insulin-dependent diabetes that affects the pancreas, or disorders that impact the entire body, such as rheumatoid arthritis, in which joints swell.

Advanced Biotherapy has designed and received a method of use patent for the exclusive use of any form of antibody - including monoclonal, humanized and fully human - to gamma interferon to treat multiple sclerosis, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis and ankylosing Spondylitis (inflammation and stiffening of the spinal cord). The company already has conducted limited clinical trials of antibodies to gamma interferon for rheumatoid arthritis and multiple sclerosis.

Through this collaboration, and under its patent protection, Advanced Biotherapy will evaluate the efficacy of the humanized antibodies when combined with the company's own treatment method. It also will continue clinical trials in Russia.

"If we can control the production of this protein, we then may be able to control the disease," said Edmond Buccellato, CEO of Advanced Biotherapy. "We believe that blocking the action of this cytokine could be the basis for a universal treatment for a host of autoimmune diseases."

New Horizon Diagnostics will develop assay systems to measure and monitor the levels of antibodies to determine effectiveness and conditions of treatment.

DOE's IPP (www.nn.doe.gov/ipp.shtml) program funded this research with the goal of creating non-defense jobs for former Soviet weapons scientists by linking them with U.S. companies interested in commercializing their non-weapons technologies. IPP projects have engaged more than 500 former weapons scientists in pursuing commercial applications.

If this antibody proves effective, the companies could patent the inventions in the United States, while the Russian scientists would control rights to produce and market the technology in the former Soviet Union. Advanced Biotherapy and New Horizon Diagnostics will match DOE's funding of $650,000 through combined in-kind donations.

Business inquiries on this or other PNNL technologies should be directed to 1-888-375-PNNL or e-mail: inquiry@pnl.gov. Advanced Biotherapy (OTCBB:ADVB) holds a patent on its treatment method for five diseases, which include four types of arthritis and multiple sclerosis. The Institute of Immunological Engineering was part of Bipreparat, the organization that once directed the Soviet Union's germ warfare program and now is a state-owned drug company. New Horizon Diagnostics develops technologies that enable the rapid identification and treatment of infectious diseases and pathogens.

Pacific Northwest National Laboratory is a DOE research facility and delivers breakthrough science and technology in the areas of environment, energy, health, fundamental sciences and national security. Battelle, based in Columbus, Ohio, has operated the laboratory for DOE since 1965.


Story Source:

The above story is based on materials provided by Pacific Northwest National Laboratory. Note: Materials may be edited for content and length.


Cite This Page:

Pacific Northwest National Laboratory. "Collaboration Advances Potential Therapy For Autoimmune Diseases." ScienceDaily. ScienceDaily, 4 June 2002. <www.sciencedaily.com/releases/2002/06/020604073301.htm>.
Pacific Northwest National Laboratory. (2002, June 4). Collaboration Advances Potential Therapy For Autoimmune Diseases. ScienceDaily. Retrieved November 20, 2014 from www.sciencedaily.com/releases/2002/06/020604073301.htm
Pacific Northwest National Laboratory. "Collaboration Advances Potential Therapy For Autoimmune Diseases." ScienceDaily. www.sciencedaily.com/releases/2002/06/020604073301.htm (accessed November 20, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

UN Says It Will Scale Up Its Ebola Response

UN Says It Will Scale Up Its Ebola Response

AFP (Nov. 20, 2014) UN Resident Coordinator David McLachlan-Karr and WHO representative in the country Daniel Kertesz updated the media on the UN Ebola response on Wednesday. Duration: 00:51 Video provided by AFP
Powered by NewsLook.com
Takata Offers "sincerest Condolences" To Victims of Malfunctioning Airbag

Takata Offers "sincerest Condolences" To Victims of Malfunctioning Airbag

Reuters - US Online Video (Nov. 20, 2014) U.S. Congress hears from a victim and company officials as it holds a hearing on the safety of Takata airbags after reports of injuries. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
Obesity Costs Almost As Much As War And Terrorism

Obesity Costs Almost As Much As War And Terrorism

Newsy (Nov. 20, 2014) The newest estimate of the cost of obesity is pretty jarring — $2 trillion. But how did researchers get to that number? Video provided by Newsy
Powered by NewsLook.com
Calling All Men: Here's Your Chance to Experience Labor Pains

Calling All Men: Here's Your Chance to Experience Labor Pains

Reuters - Light News Video Online (Nov. 20, 2014) Chinese hospital offers men a chance to experience the pain of child birth via electric shocks. Sharon Reich reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins